138 related articles for article (PubMed ID: 30191811)
1. Acute polyradiculopathy secondary to idelalisib in Relapsed Classical Hodgkin's lymphoma.
Barbieux S; Boyle EM; Baillet C; Demarquette H; Vermersch P; Morschhauser F; Herbaux C
Curr Res Transl Med; 2018 Sep; 66(3):87-89. PubMed ID: 30191811
[TBL] [Abstract][Full Text] [Related]
2. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.
Gopal AK; Kahl BS; de Vos S; Wagner-Johnston ND; Schuster SJ; Jurczak WJ; Flinn IW; Flowers CR; Martin P; Viardot A; Blum KA; Goy AH; Davies AJ; Zinzani PL; Dreyling M; Johnson D; Miller LL; Holes L; Li D; Dansey RD; Godfrey WR; Salles GA
N Engl J Med; 2014 Mar; 370(11):1008-18. PubMed ID: 24450858
[TBL] [Abstract][Full Text] [Related]
3. Idelalisib for the treatment of indolent non-Hodgkin's lymphoma.
Lopez JP; Jimeno A
Drugs Today (Barc); 2014 Feb; 50(2):113-20. PubMed ID: 24619588
[TBL] [Abstract][Full Text] [Related]
4. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
[TBL] [Abstract][Full Text] [Related]
5. Idelalisib: a review of its use in chronic lymphocytic leukaemia and indolent non-Hodgkin's lymphoma.
Keating GM
Target Oncol; 2015 Mar; 10(1):141-51. PubMed ID: 25637459
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of idelalisib, a selective inhibitor of PI3Kδ, for relapsed/refractory classical Hodgkin lymphoma.
Gopal AK; Fanale MA; Moskowitz CH; Shustov AR; Mitra S; Ye W; Younes A; Moskowitz AJ
Ann Oncol; 2017 May; 28(5):1057-1063. PubMed ID: 28327905
[TBL] [Abstract][Full Text] [Related]
7. Idelalisib for relapsed/refractory indolent B-cell non-Hodgkin's lymphoma: an overview of pharmacokinetics and clinical trial outcomes.
Davies A
Expert Rev Hematol; 2015 Oct; 8(5):581-93. PubMed ID: 26343890
[TBL] [Abstract][Full Text] [Related]
8. Idelalisib for treatment of B-cell malignancies.
Do B; Mace M; Rexwinkle A
Am J Health Syst Pharm; 2016 Apr; 73(8):547-55. PubMed ID: 26933132
[TBL] [Abstract][Full Text] [Related]
9. Management of psoriasis-like rash associated with idelalisib monotherapy in a patient with refractory follicular lymphoma: a case report.
Machan S; Plaza C; Pérez-González Y; Rodriguez-Pinilla M; Requena L; Cordoba R
J Med Case Rep; 2020 Feb; 14(1):35. PubMed ID: 32093776
[TBL] [Abstract][Full Text] [Related]
10. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.
Flinn IW; Kahl BS; Leonard JP; Furman RR; Brown JR; Byrd JC; Wagner-Johnston ND; Coutre SE; Benson DM; Peterman S; Cho Y; Webb HK; Johnson DM; Yu AS; Ulrich RG; Godfrey WR; Miller LL; Spurgeon SE
Blood; 2014 May; 123(22):3406-13. PubMed ID: 24615776
[TBL] [Abstract][Full Text] [Related]
11. Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.
Greenwell IB; Flowers CR; Blum KA; Cohen JB
Expert Rev Anticancer Ther; 2017 Mar; 17(3):271-279. PubMed ID: 28112970
[TBL] [Abstract][Full Text] [Related]
12. Idelalisib-induced colitis and skin eruption mimicking graft-versus-host disease.
Hammami MB; Al-Taee A; Meeks M; Fesler M; Hurley MY; Cao D; Lai JP
Clin J Gastroenterol; 2017 Apr; 10(2):142-146. PubMed ID: 28025783
[TBL] [Abstract][Full Text] [Related]
13. Idelalisib in relapsed/refractory diffuse large B-cell lymphoma: results from a Nordic Lymphoma Group phase II trial.
Fjordén K; Ekberg S; Kuric N; Smedby KE; Lagerlöf I; Larsen TS; Jørgensen JM; de Nully Brown P; Jerkeman M
Br J Haematol; 2022 Jan; 196(2):437-440. PubMed ID: 34435356
[No Abstract] [Full Text] [Related]
14. Phase 1b study to investigate the safety and tolerability of idelalisib in Japanese patients with relapsed/refractory follicular lymphoma and chronic lymphocytic leukemia.
Fukuhara N; Kinoshita T; Yamamoto K; Nagai H; Izutsu K; Yamamoto G; Bhargava P; Rajakumaraswamy N; Humeniuk R; Mathias A; Xing G; Fukui M; Tobinai K
Jpn J Clin Oncol; 2020 Dec; 50(12):1395-1402. PubMed ID: 32856068
[TBL] [Abstract][Full Text] [Related]
15. Retrospective Analysis of the Impact of Adverse Event-Triggered Idelalisib Interruption and Dose Reduction on Clinical Outcomes in Patients With Relapsed/Refractory B-Cell Malignancies.
Ma S; Chan RJ; Gu L; Xing G; Rajakumaraswamy N; Ruzicka BB; Wagner-Johnston ND
Clin Lymphoma Myeloma Leuk; 2021 May; 21(5):e432-e448. PubMed ID: 33516721
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.
Jones JA; Robak T; Brown JR; Awan FT; Badoux X; Coutre S; Loscertales J; Taylor K; Vandenberghe E; Wach M; Wagner-Johnston N; Ysebaert L; Dreiling L; Dubowy R; Xing G; Flinn IW; Owen C
Lancet Haematol; 2017 Mar; 4(3):e114-e126. PubMed ID: 28257752
[TBL] [Abstract][Full Text] [Related]
17. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study.
Locatelli F; Mauz-Koerholz C; Neville K; Llort A; Beishuizen A; Daw S; Pillon M; Aladjidi N; Klingebiel T; Landman-Parker J; Medina-Sanson A; August K; Sachs J; Hoffman K; Kinley J; Song S; Song G; Zhang S; Suri A; Gore L
Lancet Haematol; 2018 Oct; 5(10):e450-e461. PubMed ID: 30290902
[TBL] [Abstract][Full Text] [Related]
18. Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.
Yang Q; Modi P; Newcomb T; Quéva C; Gandhi V
Clin Cancer Res; 2015 Apr; 21(7):1537-42. PubMed ID: 25670221
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of idelalisib as bridge to allogeneic stem cell transplant in relapsed follicular lymphoma: a case report.
Marangon M; Pellegrini C; Argnani L; Zinzani PL
Tumori; 2017 Nov; 103(Suppl. 1):e41-e43. PubMed ID: 28967090
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomas.
Wagner-Johnston ND; Schuster SJ; deVos S; Salles G; Jurczak WJ; Flowers CR; Viardot A; Flinn IW; Martin P; Xing G; Rajakumaraswamy N; Gopal AK
Leuk Lymphoma; 2021 May; 62(5):1077-1087. PubMed ID: 33300385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]